{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-262539","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.522266+00:00","generated_at":"2026-05-29T22:11:32.274969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO","bullets":["Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.","Cash, equivalents, and marketable securities $137.5M as of Sep 30, 2024; plus $302.6M net IPO proceeds in Oct 2024 extend runway into H2 2027.","Phase 1 trial of SEP-786 (oral PTH1R agonist for hypoparathyroidism) ongoing; data expected mid-2025.","SEP-631 (MRGPRX2 NAM for CSU) in IND-enabling studies; TSHR NAM program for Graves' disease progressing.","Jae Kim, M.D. appointed CMO in September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-262539","json":"https://secwatch.observer/filing/0001193125-24-262539.json","markdown":"https://secwatch.observer/filing/0001193125-24-262539.md","text":"https://secwatch.observer/filing/0001193125-24-262539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/0001193125-24-262539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/d888285d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:11:32.274969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}